Molecular profiling of cancers can potentially yield novel gene markers of therapeutic prediction, which would
aid our ability to tailor targeted therapy regimens specific to each patient. Public data from gene expression profiling may
yield clues as to what oncogenic signaling pathways are deregulated in cancers, and what drugs may effectively counteract
the aberrant gene regulation patterns observed. Data are also available on panels of cancer cell lines, which have been
both profiled at the gene expression level and extensively characterized for drug responses, allowing us to identify geneto-
drug correlations. Profiling tumors from patients undergoing adjuvant or neoadjuvant drug treatment can also yield
markers of therapeutic response. In this review, we will examine recent studies aimed at our eventually being able to use
the molecular profile of a tumor to predict drug response. The profiling data from these studies is publicly available, and
can be re-examined by researchers with different questions in mind, offering us a large number of biomarker candidates
that could potentially be tested in the clinical setting.
Keywords: Gene expression profiling, oncogenic signatures, drug response prediction, molecular profile of a tumor, gene regulation, CONNECTIVITY MAP, oncogenic signaling pathways, ER+) breast tumors, biomarkers, gene transcription.
Rights & PermissionsPrintExport